share_log

Leerink Partners Upgrades Myriad Genetics to Outperform, Raises Price Target to $35

Leerink Partners Upgrades Myriad Genetics to Outperform, Raises Price Target to $35

Leerink Partners將Myriad Genetics上調至跑贏大盤,將目標股價上調至35美元
Benzinga ·  05/08 13:54

Leerink Partners analyst Puneet Souda upgrades Myriad Genetics (NASDAQ:MYGN) from Market Perform to Outperform and raises the price target from $25 to $35.

Leerink Partners分析師Puneet Souda將Myriad Genetics(納斯達克股票代碼:MYGN)從市場表現上調至跑贏大盤,並將目標股價從25美元上調至35美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論